PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
Topical treatment with Myroxylon pereirae resulted in macroscopic fistulae in only 18% of subjects compared to 90% in the control group [PMID:39981887]
Hexane extracts of Myroxylon balsamum showed growth inhibition of all methicillin-sensitive and -resistant Staphylococcus aureus strains and most Pseudomonas aeruginosa [PMID:16114081]
Oral administration of cinnamein led to significant reduction in amyloid-β plaque deposits and protection of spatial learning and memory [PMID:38910936]
Safety & adverse effects
Evidence summary
PubMed sources
- 1.PMID: 30843216 (2019) — Myroxylon pereirae resin (balsam of Peru) - A critical review of the literature and assessment of the significance of positive patch test reactions and the usefulness of restrictive diets. · Contact dermatitis
- 2.PMID: 35904413 (2023) — The estimation of permitted daily exposure (PDE) values for Myroxylon balsamum (L.) Harms var. pereirae (Royle) Harms, balsamum (balsam of Peru) for regulatory toxicology purposes: application of various toxicological strategies. · Natural product research
- 3.PMID: 19580929 (2009) — Systemic contact dermatitis. · Dermatologic clinics
- 4.PMID: 33168066 (2020) — "Peruvian balsam": an example of transoceanic transfer of medicinal knowledge. · Journal of ethnobiology and ethnomedicine
- 5.PMID: 16114081